National Cancer Institute; Meeting of the Development Therapeutics Contracts Review Committee Pursuant to Public Law 92-463, notice is hereby given of the meeting of the Developmental Therapeutics Contracts Review Committee, National Cancer Institute, National Institutes of Health, on June 23, 1994, at Gaithersburg Hilton, 620 Perry Parkway, Gaithersburg, Maryland 20877. This meeting will be open to the public from 12 p.m. to 1 p.m. on June 23 to discuss administrative details. Attendance by the

Riepilogo

National Cancer Institute; Meeting of the Development Therapeutics Contracts Review Committee Pursuant to Public Law 92-463, notice is hereby given of the meeting of the Developmental Therapeutics Contracts Review Committee, National Cancer Institute, National Institutes of Health, on June 23, 1994, at Gaithersburg Hilton, 620 Perry Parkway, Gaithersburg, Maryland 20877. This meeting will be open to the public from 12 p.m. to 1 p.m. on June 23 to discuss administrative details. Attendance by the public will be limited to space available. In accordance with provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5, U.S.C. and section 10(d) of Public Law 92-463, the meeting will be closed to the public on June 23 from 1:00 p.m. to adjournment for the review, discussion, and evaluation of individual contract proposals. These proposals and the discussions could reveal confidential trade secrets or comercial property such as patentable material and personal information concerning individuals associated with the proposals, disclosure of which would constitute a clearly unwarranted invasion of personal privacy. The Committee Management Officer, National Cancer Institute, Executi